Dr. Petros is Professor of Pharmaceutical Sciences and Mylan Chair of Pharmacology at WVU. He is also Associate Director of Anti-Cancer Development and Director of the Clinical Pharmacology and Biospecimen Processing Cores. He has published over 100 articles in the areas of pharmacokinetics, pharmacogenomics and early phase anti-cancer drug studies. He received a BS in Pharmacy (WVU), Pharm.D (Philadelphia College of Pharmacy & Sciences) and a research fellowship (St. Jude Children’s Research Hospital.) He has been continually funded as a principal or co-investigator on NIH, private foundation and pharma cancer-related grants for over 20 years.
St. Jude Children’s Research Hospital , Post-Doctoral Fellow in Pharmacometrics/Immunotherapy (1987-1990)
Philadelphia College of Pharmacy & Science, Pharm.D. (1987) Tampa VA Medical Center , Hospital Pharmacy Residency (1983-1984)
West Virginia University School of Pharmacy, B.S. Pharmacy (1983)
Hematology & Oncology
Clinical drug development in oncology
Pharmacokinetics and pharmacodynamics of new anti-cancer agents
Clinical pharmacology of hematopoietic growth factors
American Association for Cancer Research
American Society of Clinical Oncology
West Virginia University Cancer Institute
American College of Clinical Pharmacy
Hematology/Oncology Pharmacy Association
Program 4: Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program
The general focus of my research has entailed investigations concerning the clinical pharmacology of both cytokines and anti-cancer drugs. Most of the work has involved evaluation of anti-cancer drug pharmacometrics and pharmacogenetics in humans. The techniques typically entail: chromatography (HPLC +/- MS), pharmacometric modeling, and RT-PCR. The types of studies I have participated in range from those which involve traditional cytotoxic drugs in the high-dose setting to phase I (first in human) investigations of molecularly targeted agents.
I am also involved in the design and conduct of early phase treatment-related and research-related clinical trials in patients with cancer. Recent areas of focus include: development and evaluation of a drug to prevent fluorpyrimidine-induced palmar-plantar erythrodysesthesia; evaluation of drug dosing in obese patients; and elucidation of genetic factors related to chemotherapy-associated cognitive dysfunction.
My long term research goals include developing clinically feasible approaches which improve the selection and dosing of anti-cancer drugs for individual patients.